ArticleBlood2008
Tumor-specific Th17-polarized cells eradicate large established melanoma.
Article in Blood, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 478 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
478 citing papers in PubMed, 1 synthesis or guideline pooled it, 823 citations in OpenAlex.
- Pooled it
- A VEGF receptor vaccine demonstrates preliminary efficacy in neurofibromatosis type 2.Nature communications · 2019Trial
- Treatment of Patients With Metastatic Cancer Using a Major Histocompatibility Complex Class II-Restricted T-Cell Receptor Targeting the Cancer Germline Antigen MAGE-A3.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2017Trial
- Leveraging the bacteria for enhanced cancer immunotherapy: from a perspective of synthetic biology.Cancer biology & therapy · 2026Review
- C-terminal CD28 phosphorylation, pY218, modulates IL-2 secretion and therapeutic effect of CAR-T cells.Molecular therapy : the journal of the American Society of Gene Therapy · 2026Article
- CD4Science (New York, N.Y.) · 2026Article
- Contextualizing TNature reviews. Immunology · 2026Review
- Uncovering the Intricate and Heterogeneous Cellular Microenvironment of Cutaneous Melanoma.Medicina (Kaunas, Lithuania) · 2026Review
- Th17 cells require the DNA repair sensor xeroderma pigmentosum complementation Group C to control oxidative DNA damage in a murine model.Nature communications · 2026Article
- The immunology of vitiligo.Nature reviews. Immunology · 2026Review
- T-helper Transcription Factor Profiling in Peripheral Blood Mononuclear Cells: A Non-invasive Approach to Predicting Disease Stage in Breast Cancer.Biochemical genetics · 2026Article
- Commensal bacteria antigen-mediated immune response enhances anti-tumor immunity.Cancer immunology, immunotherapy : CII · 2025Article
- ProS1-MerTK signaling in CD4 T cells: implications for TIL expansion and functionality.Oncoimmunology · 2025Article
- Molecular Mechanism for the Selective Presentation of Antigenic Peptides by Major Histocompatibility Complex Class I and Class II Molecules: A Hypothesis.Current issues in molecular biology · 2025Article
- Adoptively transferred Th17 cells cooperate with host B cells to achieve durable tumor immunity.Cancer cell · 2025Article
- Activated STING in the thymic epithelium alters T cell development and selection leading to autoimmunity.The Journal of clinical investigation · 2025Article
- Deciphering Depigmentation: Mouse Models for Vitiligo Research.The Journal of investigative dermatology · 2025Review
- HPV16 E6 and E7 expressing cancer cells suppress the antitumor immune response by upregulating KLF2-mediated IL-23 expression in macrophages.Journal for immunotherapy of cancer · 2025Article
- A Phase I Dose-Escalation Clinical Trial of Bronchoscopic Cryoimmunotherapy in Advanced-Stage NSCLC.JTO clinical and research reports · 2025Article
- Targeting Neuronal Nitric Oxide Synthase (nNOS) as a Novel Approach to Enhancing the Anti-Melanoma Activity of Immune Checkpoint Inhibitors.Pharmaceutics · 2025Article
418 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
17 authors at 6 institutions in 1 country.
Funding
Abstract
CD4+ T cells can differentiate into multiple effector subsets, but the potential roles of these subsets in anti-tumor immunity have not been fully explored. Seeking to study the impact of CD4+ T cell polarization on tumor rejection in a model mimicking human disease, we generated a new MHC class II-restricted, T-cell receptor (TCR) transgenic mouse model in which CD4+ T cells recognize a novel epitope in tyrosinase-related protein 1 (TRP-1), an antigen expressed by normal melanocytes and B16 murine melanoma. Cells could be robustly polarized into Th0, Th1, and Th17 subtypes in vitro, as evidenced by cytokine, chemokine, and adhesion molecule profiles and by surface markers, suggesting the potential for differential effector function in vivo. Contrary to the current view that Th1 cells are most important in tumor rejection, we found that Th17-polarized cells better mediated destruction of advanced B16 melanoma. Their therapeutic effect was critically dependent on interferon-gamma (IFN-gamma) production, whereas depletion of interleukin (IL)-17A and IL-23 had little impact. Taken together, these data indicate that the appropriate in vitro polarization of effector CD4+ T cells is decisive for successful tumor eradication. This principle should be considered in designing clinical trials involving adoptive transfer-based immunotherapy of human malignancies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.